FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:1821 October 26, 2006 Number 17 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Perspective by Psaty, B. M. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Over the past 5 years, a series of recalls of high-profile prescription medications has aroused serious concern about the safety of the nation's drug supply. Faced with a crisis of confidence, the Food and Drug Administration (FDA) in 2004 called on the Institute of Medicine (IOM) of the National Academies to conduct a comprehensive review of the safety of prescription drugs. The IOM assembled a distinguished review committee, and after nearly a year and a half of deliberations, a draft of the committee report became public on September 21, 2006 (www.iom.edu/CMS/3793/26341/37329.aspx). The committee recommends a number of specific . . . [Full Text of this Article]

Source Information

This article was published at www.nejm.org on October 9, 2006.

This article has been cited by other articles:

• Berlin, J. A., Glasser, S. C., Ellenberg, S. S. (2008). Adverse Event Detection in Drug Development: Recommendations and Obligations Beyond Phase 3. Am. J. Public Health 98: 1366-1371 [Abstract] [Full Text]  
• Qureshi, A., Fischer, M. A. (2007). Topical Calcineurin Inhibitors Revisited. Arch Dermatol 143: 545-546 [Full Text]